Corning Jereh Pharmaceutical-B (09966): Latest research results from two Phase III clinical studies of anitumab (KN026) presented as LBA oral presentations at the 2026 ESMO Congress

Zhitong Finance APP News, Alphamab Oncology-B (09966) announces that the significant results of Anbenitamab (brand name: Ennitamab, development code: KN026), jointly developed with JMT Biological, a subsidiary of CSPC Pharmaceutical Group, for first-line treatment of HER2+ BC, and the updated OS analysis for second-line and above treatment of HER2+ GC/GEJ, were presented as a late-breaking abstract oral presentation at the 2026 ESMO Congress.